The Human Papillomavirus (HPV) Testing Market is expanding as healthcare systems place greater emphasis on cervical cancer prevention and early detection. Recent market estimates place the global HPV testing market at about USD 4.6 billion in 2025, with projections reaching USD 9.24 billion by 2035 at a 7.3% CAGR.
Testing technology is moving toward molecular and high-risk HPV detection methods, including DNA tests, mRNA tests, and genotype-specific assays. Automated platforms and improved laboratory workflows are also helping providers process larger testing volumes more efficiently.
Cervical cancer screening remains the major application for HPV testing, while diagnosis, triage, and screening for other HPV-associated cancers are also important areas. Diagnostic laboratories, hospitals, women's health clinics, and public health screening programs are key end users.
North America and Europe remain important markets because of established screening programs and advanced diagnostic infrastructure. Asia-Pacific and other emerging regions offer additional growth opportunities as organized screening expands and access to molecular diagnostics improves.
Future opportunities are likely to center on self-collected samples, high-risk HPV genotyping, automated testing, and digital integration with screening programs. These developments could make HPV testing more accessible while supporting earlier identification of patients who require further clinical evaluation.
